On March 28, 2025, Humacyte, Inc. announced its financial results for the fourth quarter and year ended December 31, 2024. The company highlighted the FDA’s approval of Symvess for extremity vascular trauma as a landmark event, marking a new era in vascular surgery.
Humacyte reported that its commercial launch of Symvess is proceeding, with 34 hospitals having initiated the Value Analysis Committee (VAC) approval process. The company made its first shipments of Symvess just 16 days after commercial inventory became available.
The potential health economic benefits of Symvess were further supported by the publication of its Budget Impact Model in the Journal of Medical Economics, which concluded that avoiding vascular infections and amputations drives cost reduction. The company also plans an IND filing in 2025 for its small-diameter ATEV for coronary artery bypass grafting.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.